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A Central nervous system (CNS) disease is the one which affects either the spinal cord
or brain and causing neurological or psychiatric complications. During the nineteenth
century, modern medicines have occupied the therapy for many ailments and are widely
used these days. Herbal medicines have often maintained popularity for historical and
cultural reasons and also considered safer as they originate from natural sources.
Embelin is a plant-based benzoquinone which is the major active constituent of the
fruits of Embelia ribes Burm. It is an Indo-Malaysian species, extensively used in various
traditional medicine systems for treating various diseases. Several natural products
including quinone derivatives, which are considered to possess better safety and efficacy
profile, are known for their CNS related activity. The bright orange hydroxybenzoquinone
embelin-rich fruits of E. ribes have become popular in ethnomedicine. The present
systematic review summarizes the effects of embelin on central nervous system and
related diseases. A PRISMA model for systematic review was utilized for search. Various
electronic databases such as Pubmed, Springer, Scopus, ScienceDirect, and Google
Scholar were searched between January 2000 and February 2016. Based on the search
criteria for the literature, 13 qualified articles were selected and discussed in this review.
The results of the report showed that there is a lack of translational research and not a
single study was found in human. This report gives embelin a further way to be explored
in clinical trials for its safety and efficacy.
Keywords: embelin, CNS disorders, neuropharmacology, neurodegenerative diseases, natural product
INTRODUCTION
Central nervous system (CNS) is an integral part of the nervous system. It consists of the brain
and spinal cord, and are associated with a number of important actions of the body. A CNS disease
can be defined as one which affects either the spinal cord (myelopathy) or brain (encephalopathy)
or both. The etiology of CNS involves a number of factors, for example, structural defects,
infections, trauma, autoimmune disorders, tumors, neurodegeneration, and others, whichmay lead
to neurological or neuropsychiatric or neurodegenerative or neurodevelopment disorders (Cannas
et al., 2002; Upadhyay, 2014). The prevalence of CNS diseases is at least two times higher in
developing countries than developed countries. According to World Health Organization (WHO),
traditional medicines have become a topic of global importance. In many developing countries,
a large proportion of the population relies heavily on traditional healers and phytomedicine for
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primary health care requirements. Concurrently, many people
in developed countries have begun to turn to alternative or
complementary therapies, including medicinal herbs (World
Health Organization, 1999; Saraf, 2012).
Embelin is chemically known as 2,5-dihydroxy-3-undecyl-1,4-
benzoquinone, which is the major active constituent of the fruits
from Embelia ribes Burm (Family: Myrsinaceae), commonly
known as “False Black Pepper” (Figure 1). It is an Indo-
Malaysian species, reported from India, Sri Lanka, Singapore,
Malaysia, and South China. Embelia ribes Burm is extensively
used in Indian, Folk, Homeopathy, Tibetian, Unani, and Siddha
traditional medicinal systems for treating various ailments like
chronic inflammatory disorders, heart and urinary conditions,
snake and insect bites, and tumor (Radhakrishnan et al.,
2012). The dried fruit is considered anthelmintic, astringent,
carminative, alterative, and stimulant (Nadkarni, 1996). Embelin
is already studied for its safety and toxicity profile in rodents and
non-rodents. It is reported that embelin is safe up to 3 g/kg orally
when tested in rodents after acute exposure. Another report on
subacute toxicity after repeated administration of embelin at 10
mg/kg dose found to be safe in rats (Poojari, 2014).
Fruits of E. ribes have been used for the treatment of central
nervous system (CNS) disorders, mental disorders and as a
brain tonic in the traditional systems of medicine. Embelin
was found to be useful in decreased cerebral infarction area
and histopathological alteration, such as normal glial density,
decreased edema, absence of lymphocytes, congestion of blood
vessels, and necrosis. These reports suggest that embelin would
be useful as an adjunct therapy for cerebral stroke and as
a potent neuroprotective agent (Thippeswamy et al., 2011).
Embelin posses all the characteristics of a compound which
can cross the blood-brain barrier (BBB) and elicit an effect on
the CNS (Pathan et al., 2009). Embelin reported for its CNS
effect by diverse mechanisms, namely by scavenging free radicals
and antioxidant effect, by inhibiting pro-inflammatory cytokines
like NF-κB and p53, by modulating sodium channel, chloride
conductance, and GABAA receptor, by inhibiting STAT3, XIAP,
and PPARγ pathways (Figure 2).
Embelin has been explored and reported for various CNS
disorders using cell lines and animal models. There is no single
study which summarizes the effectiveness of embelin in CNS
associated disorders. Although embelin proved to be effective in
laboratories against various CNS disorders, but it is not being
FIGURE 1 | Image of the plant Embelia ribes and chemical structure of
embelin.
translated to humans yet. In the present systematic review, an
effort is being made to systematically review all the literature
available with embelin in animal and clinical research.
MATERIALS AND METHODS
Search Technique
The extensive literature search was done to conduct a systematic
review summarizing the effects of embelin on central nervous
system and related diseases. Various electronic databases were
used, namely Pubmed, Springer, Scopus, ScienceDirect, and
Google Scholar between the period January 2000 and February
2016. The following keywords were searched individually and in
combination with the embelin: brain, trauma, CNS, neurological
disorder, neurodegenerative disease, and psychological disorder.
Study Selection and Exclusion/Inclusion
Criteria
The search was limited to, articles published in English language
and original research articles only. Abstracts of symposiums and
conferences, review articles, books, and patents were excluded
due to insufficient information for evaluation and comparison.
Articles which were not related to CNS diseases were excluded.
Any clinical, pre-clinical, ex-vivo, and in-vitro studies were also
the part of the inclusion criteria.
Data Extraction
Two separate researchers obtain data independently, and then
the titles and abstracts of each article were compared to delete
duplication of the data. Based on thementioned eligibility criteria
for the literature search, 14 articles were excluded and 13 qualified
articles were evaluated in this study. The aim of using PRISMA
statement is to help authors to understand and improve the
reporting of systematic reviews and meta-analyses related to use
of embelin in CNS related disorders (Moher et al., 2015). Flow
diagram was prepared according to the guidelines of PRISMA-
Transparent reporting of systematic reviews and meta-analyses
(Moher et al., 2009).
RESULTS AND DISCUSSION
The search based on the keywordsmentioned in themethodology
yielded 6,448 records. After applying exclusion criteria, total
articles removed were 6,435, which includes; (a) 3,470 reviews,
book and patents, (b) 2,090 did not meet review criteria, (c) 402
abstracts, (d) 459 duplicates, and (e) 14 not relevant to the aim
of the review based as they deal with formulations of the embelin
(Figure 2). Thirteen eligible articles were included, compiled in
Table 1 and discussed in the present systematic review (Figure 3).
Anticonvulsant Activity
Mahendran et al. (2011b) isolated embelin from the berries of E.
ribes and reported on the anticonvulsant activity of the embelin
using maximal electroshock (MES) and pentylenetetrazole
(PTZ). MES cause the spread of seizure similar to grandmal
epilepsy. In MES method, brief high-intensity shock is applied
to the head through corneal or ear electrodes with a stimulator
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FIGURE 2 | Mechanism of action of embelin on various CNS disorders.
that either delivers a constant current to constant voltage at a
frequency of 50–60/s. The MES convulsions are divided into
five phases such as the phase of tonic limb flexion, the phase of
tonic limb extension, the phase of clonic convulsions, stupor, and
recovery or death (Castel-Branco et al., 2009). Protection against
hind leg tonic extension (HLTE) in MES predicts the ability
of embelin to prevent the spread of seizure discharge from the
epileptic focus in the brain and suppressing generalized tonic–
clonic and partial seizures. Phenytoin is said to protect against
seizures by causing blockage of voltage-dependent, voltage-gated
sodium channels. This block sustains repetitive high-frequency
firing of action potentials. The results show that there is a
complete absence of HLTE in MES model when treated with
embelin 10 mg/kg dose in comparison with phenytoin. It shows
that embelin at 10 mg/kg dose might act via blockade of
voltage-gated sodium channels. Embelin at 2.5, 5, and 10 mg/kg
shows, dose-dependent activity against MES model which act
of sustaining repetitive high-frequency firing of action potential
exhibiting anticonvulsant activity. Pentylenetetrazole (PTZ) is
used to induce clones seizure-like behavior with increased
locomotor activity. The increased chloride conductance drives
the membrane potential toward the reversal potential of the Cl↓
ion which is about –65 mV in neurons, inhibiting the firing
of new action potentials. This mechanism is responsible for
the anti-epileptic effects of GABAA allosteric agonists. Embelin
might increase chloride conductance which drives membrane
potential, inhibiting the firing of action potential delaying onset
of a clonic-tonic seizure in PTZ induced epilepsy. PTZ basically
acts at the picrotoxin site of the GABAA receptor and reduces
chloride conductance which further leads to glutamate excitation
(Desmond et al., 2012).
For each seizure model, embelin was administered
intraperitoneally 30 min prior to the induction of MES and
PTZ. Administration of embelin (2.5 and 5 mg/kg, i.p.) showed
significant (P < 0.001) reduction in the duration of HLTE
compared to the control. Based on the results, the study
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TABLE 1 | Pharmacological activities reported with embelin in central nervous system related disorders.
Sr.
no.
CNS activity Study sample Source of embelin Dose Result Number of
citations
Author
(year)
1 Anticonvulsant
activity
Swiss albino rats
(150–200 g; n = 6)
Swiss albino mice
(20–25 g; n = 6)
Embelin isolated
from berries of
Embelia ribes
2.5, 5, and
10mg/kg
• ↓ in the duration of HLTE in MES
(2.5 and 5mg/kg, i.p.).
• Electroshock—100% protection
against mortality.
• ↑ Clonic and tonic onsets at all
dose.
54 Mahendran
et al., 2011b
2 Antidepressant
activity
Swiss albino mice
(20–25 g; n = 6)
Embelin isolated
from berries of
Embelia ribes
2.5 and
5mg/kg
• Antidepressant-like effect in Tail
suspension test (TST).
• ↓ Immobility in the Forced
swimming test (FST).
• Exhibited significant activity in
mice TST and FST experimental
models.
6 Gupta et al.,
2013
3 Anxiolytic activity Swiss albino mice
(n = 6)
Embelin isolated
from berries of
Embelia ribes
2.5 and
5mg/kg
• ↑ Time spent and number of
entries in open arm (elevated plus
maze).
• ↓Decrease in the duration of
immobility in light box (light and
dark model).
• ↑Increase rearing assisted rearing
and number of square crossed
(open field test).
• Embelin showed its anxiolytic
effect in dose-dependent manner.
6 Afzal et al.,
2012
4 Sickness behavior Male Swiss albino
mice (25–30 g;
n = 8)
Embelin isolated
from berries of
Embelia ribes
10 and
20mg/kg
• Embelin prevented anhedonia,
anorexia.
• Ameliorated brain oxidative stress
markers.
• Protective effect of embelin in
LPS-induced sickness behavior in
mice.
0 Shaikh et al.,
2016
5 Huntington’s disease Adult Wistar rats
(190–220 g; n = 8)
Embelin isolated
from berries of
Embelia ribes
10 and
20mg/kg/day
• Loss of body weight.
• Decreased the oxidative stress.
• Decrease of 69–76% brain lesion.
• Protect the neurons from 3-NP
toxicity.
1 Dhadde et al.,
2016
6 Multiple sclerosis
(Autoimmune
encephalomyelitis,
CNS inflammation)
Female C57BL/6
mice, aged 6–8
weeks (n = 6)
Embelin pure form 25 and
50mg/kg
• ·↓ Human CD14+
monocyte-derived dendritic cell
differentiation.
• ·↓Duction in the EAE
(experimental autoimmune
encephalomyelitis) clinical score.
• ·↓ Inflammatory Th1 and Th17
cells in EAE.
9 Xue et al.,
2014
7 Traumatic brain
injury
Female
Sprague–Dawley
rats, male C57BL/6
mice(n = 10)
Embelin pure form 200 nM • Inhibition of NF-κB expression of
XIAP increases in PFT-treated
animals.
• p53 and NF-κB dependent
mechanisms delayed
neurodegeneration
62 Plesnila et al.,
2007
8 Hypoxia-ischemia
(HI) induced
neurological injury
Female and male
Wistar rats pups
(n = 15)
Embelin pure form
(Sigma-Aldrich,
USA)
20mg/kg
embelin
• Confirm sex differences in
behavioral and anatomical
outcome.
• XIAP acts to protect the female
brain from the early HI injury.
18 Hill et al.,
2011
(Continued)
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TABLE 1 | Continued
Sr.
no.
CNS activity Study sample Source of embelin Dose Result Number of
citations
Author
(year)
9 Global
ischemia/reperfusion-
induced brain
injury
Male Wistar rats
(200–260g; n = 6)
Extraction of
embelin from
Embelia ribes
25 and
50mg/kg
• ↑ Locomotor activity and hanging
latency time.
• ↓ Beam walking latency.
• ↓ Lipid peroxidation.
• ↑ Total thiol content and
glutathione-S-transferase
neuroprotective agent and useful
in the treatment of stroke.
22 Thippeswamy
et al., 2011
10 Focal cerebral
ischemia brain
Male Wistar rats
(200-250 g; n = 6)
Embelin isolated
from berries of
Embelia ribes
50, 75,
100mg/kg
• Decreased the infarction and
edema (100mg/kg).
• Decreased MDA level (75 and
100mg/kg).
• ↑ SOD and CAT (100mg/kg).
0 Patel and
Gohil, 2014
11 Cerebral ischemia C57BL/6 male, GI
female, and Ovx
female mice(n = 7)
Embelin pure form
(Sigma-Aldrich,
USA)
20mg/kg • Inhibitor of XIAP exacerbated
stroke-induced injury in females
but had no effect in males.
97 Siegel et al.,
2011
12 Apoptosis in human
glioma cells via
NF-κB inhibition
Human glioma cell
lines T98G, U87MG,
and H4.
Immortalized
primary human fetal
astrocytes
(IM-PHFA)
Embelin pure form
(Sigma-Aldrich,
USA)
(0–50µM) • Embelin suppressed proliferation
of human glioma cells.
• Apoptosis in human glioma cells
by inhibiting NF-κB.
• ↓ NF-κB activity by reducing
nuclear translocation of p65.
20 Park et al.,
2013
13 Apoptosis in human
glioma cells via the
mitochondrial
pathway
Human brain glioma
U87 cells
Embelin pure form
(Sigma-Aldrich,
USA)
(0, 50, and
100µg/ml)
• Time- and dose-dependent
apoptosis of brain glioma cells.
• Arrest the cell cycle in the G0/G1
phase.
• Changes in brain glioma cell
mitochondrial membrane
potential.
• Shifting of Bax and Bcl-2 to cause
apoptosis.
6 Wang et al.,
2013
demonstrated that embelin at 10 mg/kg dose could significantly
reduce the duration of the HLTE in MES model. Embelin
at all the three doses significantly (P < 0.001) decreased the
onset of stupor when compared to the control. Eventually,
the percentage protection reported was 100% as no mortality
was observed in all the embelin treated rats when challenged
with maximum electroshock. On the other hand, embelin
significantly delayed the onset of clonic and tonic seizures with
an increased in a survival rate in a dose-dependent manner
when checked against PTZ. Embelin also exhibited significant
and dose-dependent delayed the onset of clonic-tonic actions
and protection from PTZ induced mortality. At 5 and 10 mg/kg
doses, it exhibited 50 and 83.33% protection against mortality.
This study does not include the effectiveness of embelin in
chronic models of epilepsy like lithium-Pilocarpine, kindling,
or intracerebroventricular kainic acid. Based on the preliminary
results, Mahendran et al. (2011a) postulated that embelin is
a potent anticonvulsant phytocompound and the plausible
mechanism is through GABAergic modulation. But, there
was no supporting information like brain GABA estimation
or GABA receptor expression were included in the published
report.
Antidepressant Activity
Depression is one of the common neuropsychiatric disorder
which contribute to the global burden of the diseases affects
about 1 in 20 people across the world (Currie and World
Health Organization Regional Office for Europe, 2000). Gupta
et al. (2013) reported the anti-depressant effect of embelin
in experimental animals using two universally accepted
experimental models: mice tail suspension test (TST) and forced
swimming test (FST). Embelin was isolated from fresh fruits
of E. ribes. The TST is used as an experimental method in
scientific research to measure stress in rodents. The FST—in
a rodent is used for evaluation of the antidepressant efficacy
of new compounds, antidepressant drugs, and experimental
development that are aimed at translating or preventing
depressive-like states. It is based on the observation that if
an animal is subjected to short term inescapable stress then
it will become immobile. It has been described as rendering
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FIGURE 3 | Flow chart of study selection procedure.
a situation in which “behavioral despair” is induced; that is,
the animal loses hope to escape the stressful environment.
It is well-known that compounds which selectively bind to
high-affinity benzodiazepine receptors possess both anxiolytic
and antidepressant effects. The anxiolytic effect of embelin was
shown to be mediated through the effect on the GABA system.
The similar mechanism of antidepressant action cannot be ruled
out (Afzal et al., 2012). It is, therefore, reasonable to assume that
the observed antidepressant-like activity of embelin could be
attributed to its known antioxidant effect. GABAA receptors are
allosteric modulatory sites for benzodiazepine. They are probably
composed of five protein subunits, at least some of which belong
to different subunit classes. So far GABAA receptors have been
identified as six alpha–four beta–three gamma-, and delta-
and two-rho = p subunits. A 3D-structural model similarity,
further shows that embelin is closely related with the well-known
antioxidant alpha-tocopherol (AT, vitamin E), especially in the
long-chain non-polar tails and polar phenolic heads (Lobato
et al., 2010). Embelin at 2.5 and 5 mg/kg dose administered orally
and tested using tail suspension test (TST) and forced swimming
test (FST) in mice. It was found to effectively reduce immobile
time in both experimental models suggesting its antidepressant
potential. Embelin (5 mg/kg) was reported to be comparably
better than the standard antidepressant drug, imipramine (15
mg/kg), which is a tricyclic antidepressant drug (Gupta et al.,
2013). As a criticism, Gupta et al. (2013) fail to mention about
actual activity of embelin as an anti-depressant, which may
be via inhibiting 5-hydroxytryptamine receptors (5-HT) and
noradrenaline (NA) reuptake. In their study, imipramine was
used as a positive control which has the known antidepressant
activity and it acts by inhibiting NA and 5-HT reuptake into
neurons.
Anxiolytic Activity
Anxiety is a feeling of discontent, such as fear or worry that can
be intense or gentle. Everyone has feelings of anxiety at some
point in their life for example, you may feel worried and anxious
about a job interview or having a medical examination or sitting
an exam. An anxiolytic is a medication or other intervention
that inhibits anxiety. This effect is in contrast to anxiogenic
agents, which increases anxiety. Afzal et al. (2012) revealed
the anxiolytic potential of embelin using behavioral models of
anxiety. The elevated plus maze (EPM) is a test used to measure
anxiety in laboratory animals. The test uses two open and two
enclosed arm apparatus with an elevated, plus-shaped (+). The
behavioral model is based on the general disinclination of rodents
to open spaces. This disinclination leads to the behavior termed
thigmotaxis, a greater liking to remain in enclosed spaces or
close to the edges of a bounded space. Reduction in anxiety
is indicated in the plus-maze by an increase in the amount of
time spent or entries in the open arms (time or entries in open
arms/total time or total entries in open or closed arms; Walf
and Frye, 2007). Open field test (OFT) is an experiment used
to assay general locomotor activity levels and anxiety in rodents.
Rodents display a natural aversion to brightly light areas. They
also have an urge to explore a perceived threatening stimulus.
The result of these two conflicting drives is anxiety. The increase
in exploratory behavior leads to decreased anxiety. Increased
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anxiety will result in less locomotor motion and the animal will
have a preference to remain at the edges of the field (Ramos,
2008). The light/dark test is based on the natural version of
rodents to brightly illuminated areas and on the spontaneous
exploratory behavior of rodents in response to mild stress, that
is, novel environment and light. The test apparatus consists of a
small dark safe compartment (one-third) and a large illuminated
preference compartment (two-thirds; Bourin andHascoët, 2003).
Embelin at 5 mg/kg dose significantly increased the percentage
of time spent and the number of entries in open arm in EPM
apparatus. Percentage of time spent in the open arms and number
of open arm entries was significantly (P < 0.01 and P < 0.001)
increased by embelin (2.5 and 5 mg/kg) and diazepam. Time
spent in the open arm by animal treated with embelin 2.5 and
5 mg/kg dose was 47.92 ± 1.25 and 66.17 ± 1.93 and no. of
entries in the open arm by animal treated with embelin 2.5 and
5 mg/kg dose was 5.61 ± 0.47 and 7.90 ± 0.45 significant. The
result shows that embelin exhibited dose-dependent activity as
an anxiolytic in mice EPM-test. In the open field test, embelin
exhibited a significant increase in a number of rearing, assisted
rearing and number of the crossing. A number of rearing in
open field test by animal treated with embelin 2.5 and 5 mg/kg
dose was 17.68 ± 0.52 and 20.33 ± 0.59 and number of assisted
rearing in open field test by animal treated with embelin 2.5
and 5 mg/kg dose was 16.20 ± 1.00 and 21.12 ± 1.2. In light
and dark model, embelin produced a significant increase in time
spent, the number of crossing and decrease in the duration of
immobility in a light box. The animals treated with diazepam
(1 mg/kg) and embelin (2.5 and 5 mg/kg) showed significant (P
< 0.05 and P < 0.001) increase in the time spent in the lighted
box and decrease in the time spent in the dark box. Time spent
in the lighted box (s) by animal treated with embelin 2.5 and 5
mg/kg dose was 94.92± 1.73 and 116.8± 4.24 and time spent in
a dark box (s) by animal treated with embelin 2.5 and 5 mg/kg
dose was 167.0 ± 4.59 and 148.3 ± 1.26. Embelin at 2.5 mg/kg
dose, failed to produce any significant change in the number
of crossing and duration of immobility. Afzal et al. (2012)
concluded that embelin exhibits significant anxiolytic activity
in a dose dependant manner. They proposed that the observed
activity could be due to an antagonistc effect on GABA receptor
complex as most of the anxiolytic and antidepressant molecules
selectively bind to high-affinity benzodiazepine binding site,
present on GABA receptor. Both Gupta et al. (2013) and Afzal
et al. (2012) contradicted about vehicle used to dissolve embelin,
they mentioned two different vehicles, olive oil and 1% Tween 80
(v/v) as embelin has poor water solubility.
Sickness Behavior
During the course of an infection, the adaptive behavioral
changes that develop in ill individuals is known as sickness
behavior. It is relevant to understand depression and some
aspects of the suffering in any disease. Sickness behavior is like a
complex behavior induced by infections and immune trauma and
mediated by pro-inflammatory cytokines. Some of the evidence
state that sickness behavior is mediated through the effects of
pro-inflammatory cytokines (PICs), such as IL-1, TNFα, and
IL-6 (Maes et al., 2012). Embelin has been reported to possess
neuroprotective, anxiolytic and antiinflammatory assets and has
been shown to inhibit Nf-κB pathway and cytokine production
(Mahendran et al., 2011a). Few characteristics of the behavioral
pattern including malaise, hyperalgesia, pyrexia, listlessness, and
disinterest in social interactions with the environment, lethargy,
behavioral inhibition, exploration and grooming, reduction of
reproductive performance, anorexia and weight loss, failure to
concentrate, and anxiety (Maes et al., 2012). The effect of embelin
was evaluated in sickness behavior in mice by Shaikh et al. (2016).
Adult male Swiss albino mice were pre-treated with embelin
(10 and 20 mg/kg per oral) for 3 days and then challenged
with lipopolysaccharide (LPS; 400 µg/kg intraperitoneal). In
EPM-test, pre-treatment with embelin (10 and 20 mg/kg) and
dexamethasone (1 mg/kg) significantly reversed LPS-mediated
effects and increased both the number of open arm entries
(3.00 ± 0.53, 3.12 ± 0.58 and 3.12 ± 0.47, respectively) and
time spent in open arm (15.38 ± 3.19, 14.00 ± 2.67 and
13.63 ± 1.94 s, respectively) when compared with LPS-alone. In
light–dark box test, Pre-treatment with both the tested doses
of embelin and dexamethasone (1 mg/kg) prior to LPS-shot
significantly increased the time spent in the light compartment
(33.88 ± 2.11, 43.75 ± 6.81 and 34.13 ± 4.38 s, respectively).
In the forced swim test, embelin (10 and 20 mg/kg) prior to
LPS-injection significantly decreased the floating time (78.75
± 5.03 and 62.88 ± 5.03 s, respectively) when compared with
LPS-alone-administered group. In social behavior tests, social
exploration was measured just before the administration of LPS
and again 2, 4, 8, and 24 h later. LPS-associated reduction in
social behavior was attenuated by pre-treatment with embelin
10mg/kg (20.61 ± 4.15%, 29.24 ± 8.45% and 56.61 ± 5.44%,
respectively) and 20 mg/kg (38.41 ± 5.90%, 44.78 ± 5.17% and
63.55 ± 5.95%, respectively), dexamethasone 1 mg/kg (43.84
± 5.31% 49.12 ± 2.95% and 64.87 ± 4.42%, respectively)
when compared with LPS-alone-treated animals. In the open
field test, pre-treatment with embelin (10 and 20 mg/kg) and
dexamethasone (1 mg/kg) significantly attenuated LPS-induced
changes and increased the peripheral, central and total number
of line crossings and a number of climbs rear when compared
with LPS-alone-treated group. Food and water intake test, pre-
treatment of LPS-challenged mice with embelin (10 and 20
mg/kg) and dexamethasone (1mg/kg) significantly reversed LPS-
induced anorexia and adipsia in comparison to animals with
LPS-alone-treated group. This all comparative finding eventually
concluded that embelin is neuroprotective against LPS-induced
sickness behavior in mice (Shaikh et al., 2016).
Huntington’s Disease
Huntington’s disease (HD) is a progressive neurodegenerative
disorder associated with severe degeneration of basal ganglia
neurons, which affects muscle coordination and leads to mental
decline and behavioral symptoms. Systemic administration of 3-
nitropropionic acid (3-NP), an inhibitor of the mitochondrial
citric acid cycle, results in a progressive locomotor deterioration
resembling that of HD. It differs mechanistically from excitotoxic
lesions in that 3-NP irreversibly inhibits the mitochondrial
citric acid cycle and leads to depressed ATP levels and elevated
lactate concentrations (Borlongan et al., 1997; Brouillet, 2014).
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The study carried out by Dhadde et al. (2016) evaluated the
neuroprotective potential of embelin against 3-nitropropionic
acid (NP) induced experimental HD in rats. 3-NP significantly
altered the behavioral and neuronal antioxidant status and caused
significant neuronal damage in the striatal region. Elevated levels
of malondialdehyde (MDA) and decreased levels of antioxidants
(GSH, GST, and CAT) in the 3-NP treated rat brains supports
the increased oxidative stress in HD. Behavioral tests were carried
in the following order: neurological scoring, locomotor activity,
EPM-test, beam walking test and hanging wire test. Biochemical
estimation and brain lesion measurement were carried out in
order to explore the molecular and structural differences of
embelin in the brain. Administration of 3-NP alone shows motor
abnormalities, decreased locomotor counts, loss of memory
in EPM, decreased motor coordination in beam walking test,
decreased hanging latency on hanging wire test and even 3-
NP alone treatment resulted in highly significant (p < 0.001)
reduction in body weight. In neurological scoring, none of the
rats in embelin treated groups (10 and 20 mg/kg) showed hind
limb paralysis and inability to move indicating its potent activity
in reversing 3-NP induced motor abnormalities. The treatment
with embelin at both the doses (10 and 20 mg/kg) reversed
the decrease in locomotor counts induced by 3-NP toward the
normal, and it was found to be 129.2± 5.58 and 160± 11.14, thus
both the doses of embelin showed improvement in the locomotor
count. In the EPM-test, embelin treatment at 10 mg/kg body
weight significantly (p < 0.01) Reversed the memory loss (27.73
± 3.92%) induced by 3-NP toward the normal, when compared
with 3-NP alone treated animals. However, embelin at 20 mg/kg
body weight dose showed a complete reversal of 3-NP induced
memory loss same as a normal control group. At beam walking
test, treatment dose of embelin (10 and 20mg/kg) to 3-NP treated
rats significantly (p < 0.001) improved the motor coordination
and body balance. These animals traversed the beam in 5.11 ±
0.66 and 5.51± 0.72 s, respectively. In hanging wire test, embelin
at doses of 10 and 20 mg/kg increased 3-NP induced decrease in
hanging latency period, with values 36.66 ± 1.78 (p < 0.05) and
49.34± 2.62 s. The percentage decrease in the brain lesion area in
both these groups was 69.59 and 76.21%, respectively. Embelin at
10 and 20 mg/kg to 3-NP treated animals significantly (p < 0.01)
reduced the brain lesion area to 4.32 ± 0.44 and 3.38 ± 0.17%,
respectively. Embelin treatment significantly protected neurons
against 3-NP induced toxicity and reduced brain lesion up to
76%. It also exhibited a significant antioxidant and improved
behavioral alterations induced by 3-NP. It is postulated that
effectiveness of embelin could be due to its antioxidant potential
and ability of embelin to modulate Ca2+ influx associated with
increased brain glutamate levels (Dhadde et al., 2016). In 3-NP
induced HD like condition model in rats, embelin found to be
effective neuroprotectant.
Multiple Sclerosis (MS)
A chronic, typically progressive damage to the sheaths of
nerve cells in the brain and spinal cord is termed as multiple
sclerosis (MS). Symptoms may include numbness, impairment
of speech and muscular coordination, blurred vision, and severe
fatigue (Loma and Heyman, 2011). Animal models of brain
inflammation are used to study autoimmune encephalomyelitis,
or experimental allergic encephalomyelitis (EAE). Dendritic cells
(DCs) have a pivotal role in the immune response and in
stimulating naïve T-lymphocytes. Induction and maintenance
of self-tolerance is a critical role of DCs and the failure of
which can lead to autoimmune/inflammatory diseases. Embelin
concentrations of 10, 30, and 60 µM, inhibits the differentiation
and endocytosis of Human Monocyte-Derived dendritic cell
(DCs). Compared with the day 5 untreated iDCs, a significant
dose-dependent reduction in cell surface marker expression was
observed in EB-treated cells. These results indicate that embelin
inhibited the differentiation of human CD14+ monocytes into
DCs in a dose-dependent manner. DC-derived cytokines are
required for the polarization of the adaptive immune response.
Therefore, Xue et al. (2014) investigated the potential effects of
embelin on the regulation of the expression of the cell-polarizing
cytokines. The production of the inflammatory cytokine tumor
necrosis factor-alpha (TNF-α), the Th1 cell polarizing cytokine
IL-12p35, the Th17 cell-polarizing cytokines IL-6 and IL-
12/23p40, and the Th1 cytokine IFN-γ is substantially inhibited
by embelin. Embelin suppressed the DC-mediated polarization
of Th1 and Th17 cells and that it may be useful for the treatment
of autoimmune inflammatory diseases that are mediated by
Th1 and Th17 cells. Embelin ameliorates the clinical severity of
experimental autoimmune encephalomyelitis (EAE). Compared
with PBS-treated mice, the incidence of clinical symptoms in
the 25 and 50 mg/kg/day EB-treated mice were reduced. These
data suggest that embelin significantly ameliorates the clinical
outcome of EAE. TGF-β/β-catenin and STAT3 signaling pathway
are used by embelin to inhibit DC function, which leads to a
reduction in the EAE clinical score and in CNS inflammation
and demyelination. The novel finding of this study is that
the anti-inflammatory effect of embelin appears to require the
presence of functional TGF-β/β-catenin and the absence of
activated STAT3 in DCs. It was also found that embelin-induced
inhibition of the differentiation of Th1 and Th17 cells was
associated with a down regulation of the production of Th1-
polarizing and Th17-polarizing. Embelin, a novel XIAP inhibitor,
significantly increased TGF-β/β-catenin signaling and decreased
STAT3 phosphorylation in DCs (Xue et al., 2014).
Embelin is a potent inhibitor of the activation of pro-
inflammatory transcription factors, such as nuclear factor kappa
B and signal transducer and activator of transcription 3 (STAT3;
Heo et al., 2011). Embelin has been shown to inhibit the X-
linked inhibitor of apoptosis protein and various inflammatory
pathways (Ahn et al., 2007). In one of the study, Xue et al. (2014)
demonstrated that embelin possess a strong therapeutic potential
for autoimmune inflammatory conditions in MS. The study
revealed the role of embelin in modulating newer regulatory
mechanisms and molecular targets essential for the effectiveness
in EAE. Therefore, these reports suggest that embelin could be
used as a therapeutic agent to control pathological conditions,
such as MS and other inflammatory autoimmune diseases, that
are induced by the functional expansion of Th1 and Th17 cells.
Traumatic Brain Injury
Traumatic brain injury (TBI) is one of the common causes of
mortality in both children and young adults. Survivors have
many complications like brain edema and programmed death of
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neuronal cells following acute and chronic neurodegeneration.
The study carried out by a team from five European institutes
addresses the role and interaction of p53 and NF-κB-dependent
mechanisms in TBI induced delayed neurodegeneration (Plesnila
et al., 2007). Neuroprotection mediated by PFT is reversed
by embelin in three different in-vitro models of neuronal cell
death induced by camptothecin, glutamate, or oxygen-glucose
deprivation (OGD). Embelin was used to evaluate whether
enhanced X-chromosomal linked inhibitor of apoptosis (XIAP)
levels is indeed involved in neuroprotection by pifithrin-a
(PFT). Hence, they strongly suggest the involvement of NF-κB
dependent regulation of XIAP in the observed neuroprotective
effect (Plesnila et al., 2007).
Hypoxia-Ischemia (HI) Induced
Neurological Injury
Hypoxia-ischemia (HI) occurs when there is a deficiency in both
oxygen and blood supply, which results in neonatal neurological
impairment. Hill et al. (2011) tested on the caspase-dependent
progression of apoptosis using embelin which is known as
potent XIAP inhibitors in order to prove that sexes influences
in differing pathways of cell death due to HI. So they found
out that embelin inhibits XIAP by binding to BIR3 domain
and thus eventually increase in cell death through a caspase-
dependent pathway. Similarly, the behavioral outcomes showed
that through XIAP inhibition, HI induced female rats possess
severe behavioral deficits compared to HI males. These in-
vivo data revealed that there were significant differences in
severity of cognitive deficits in male infants compared to female
infants with HI. This phenomenon supports the evidence of
activation of caspase-independent cell death in males compared
to females that activate caspase-dependent cascade following
neonatal ischemia. By using embelin as XIAP inhibitor, they
could conclude that gender influences cell death mechanism
following HI injuries and suggest that it is very important to
develop a sex-specific neuroprotection to cure HI.
Ischemic Stroke
The majority of strokes occur when blood vessels to the brain
become narrowed or clogged with fatty deposits called plaque,
This cuts off blood flow to brain cells. A stroke caused by
lack of blood reaching part of the brain is called an ischemic
stroke. Stroke is the third major cause of mortality and the
leading cause of long-term disability. Ischemic stroke accounts
for ∼80% of all strokes (Jauch et al., 2013). Ischemic stroke
can be divided into two main types: thrombotic and embolic.
Deprived of oxygen and other nutrients, the brain suffers damage
as a result of the stroke. A thrombotic stroke occurs when
diseased or damaged cerebral arteries become blocked by the
formation of a blood clot within the brain (Rha and Saver,
2007). In order to investigate the mechanisms underlying injury
after ischemic stroke as well as to develop effective therapeutic
approaches to the disease, several ischemic stroke models have
been developed in a variety of species. Models of stroke that
can be used in rodents are becoming increasingly popular at the
bench because (1) genetically-engineered animals; (2) a number
of neurosensory and motor behavior outcomes; (3) fewer animal
welfare concerns. In general, there are four major types of animal
models of ischemic stroke: (1) complete global cerebral ischemia;
(2) incomplete global ischemia; (3) focal cerebral ischemia and
(4) Multifocal cerebral ischemia (Liu and McCullough, 2011,
Figure 4).
Global Ischemia
Brain tissue and cells require oxygen and nutrients to sustain
survival and contribute to standard neural operating procedures
which are deprived in the a global ischemic event. This leads
to the death of brain tissue or cerebral infarction/ischemic
stroke which is due to poor oxygen supply or cerebral hypoxia.
Siegel et al. (2011) also hypothesized that caspase dependent
mechanism of ischemic cell death is also influenced by gender
differences. They found that XIAP mRNA level was higher in the
normal female mice brain compared to stroke induced female
mice whereas no differences were observed in the male brain.
They reported that embelin decreased the association between
XIAP and Caspase-3 in both sexes and was acting as an XIAP
inhibitor. Based on the results, larger brain infarcts were seen
in embelin treated ovariectomized (Ovx) females compared to
gonadally intact (GI) females. The effects of embelin on infarct
exacerbation may be due to independent of circulating estrogen
levels. Siegel et al. (2011) concluded that embelin treatment
significantly increases stroke-induced injury in females but had
no effect inmales. This shows that XIAP is an importantmediator
of sex-specific responses after stroke.
Thippeswamy et al. (2011) investigated the protective role
of embelin in transient global ischemia induced by occluding
bilateral common carotid arteries followed by reperfusion.
Embelin pre-treated rats significantly improved locomotion.
Vestibulomotor function was assessed by beam walking test and
pre-treatment with embelin significantly decreased beamwalking
latency when compared with ischemic control animals. Grip
strength was measured using Hanging Wire test and embelin
treated animals had better and longer hanging time compared
to ischemic control. The behavioral observations were very well-
supported by biochemical estimations, where embelin found to
be modulating the lipid peroxidation, the total thiol content
and glutathione-S-transferase activity in brain homogenates.
Histopathological studies confirmed, decrease in the infarct size
in embelin-treated animals.
Focal Cerebral Ischemia
Cerebral ischemia is characterized by the inadequate oxygenated
blood supply to the brain leads to the death of brain tissue It
has been well-studied that reactive oxygen species play a key
role in the pathogenesis of cerebral ischemia (Woodruff et al.,
2011). Embelin is reported to have potent antioxidant activity
and its chemical structure is similar to antioxidant coenzyme
Q10 (Matthews et al., 1998). Patel and Gohil, investigated the
effect of embelin against focal cerebral ischemia using the middle
cerebral artery occlusion (MCAO) model. The model of MCAO
involves the insertion of a surgical filament into the external
carotid artery and threading it forward into the internal carotid
artery (ICA) until the tip occludes the origin of the MCA,
resulting in a cessation of blood flow and subsequent brain
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FIGURE 4 | Animal models of ischemic stroke model.
infarction in the MCA territory. Male Wistar rats were treated
with embelin (50, 75, and 100 mg/kg, p.o.) for 20 days, followed
by MCAO-induced focal cerebral ischemia and the parameters
evaluated were infarct size and score. The antioxidant evaluation
includes MDA, superoxide dismutase (SOD), and catalase (CAT)
in brain homogenates. Embelin significantly decreased infarct
size and improved infarct score. Embelin also decreased the
MDA level whereas increased SOD and CAT level as compared
to ischemic control group. The probable mechanisms by which
embelin could be effective in cerebral ischemic condition is by
the restoration of altered antioxidant enzyme activity as well as
decreasing the production of lipid peroxides (Patel and Gohil,
2014). Some herbal medicines or their products having anti-
oxidant activity have been suggested to protect against ischemic
reperfusion injury, and thus justifying their use in cerebral
ischemic patients.
Brain Cancer/Apoptosis in Human Cancer
Cells
NF-κB Inhibition
Glioblastoma is known to be the most aggressive primary brain
malignancy with median survival rates (Chou et al., 2015).
Embelin is an active compound that acts an inhibitor for NF-
κB, STAT3, XIAP, and PPARγ to induce growth suppression and
apoptosis in human cancer cells (Park et al., 2013). Embelin is
a small-molecule inhibitor of an XIAP, which has the ability
to specifically inhibit XIAP of various types of a tumor cell to
control and regulate the apoptosis (Wang et al., 2013). A recent
finding shows that embelin also enhanced TRAIL-mediated
apoptosis Allensworth et al. (2012) and thus on the basis of
above reference study, Park et al. (2013) suggested that embelin
may be a good anti-cancer agent with less toxicity in normal
cells. IκBs regulate nuclear translocation and activation of NF-κB,
embelin decreases phosphorylation of IκBα in a dose- and a time-
dependent manner, which indicates that embelin activates IκBα
that is a negative regulator of NF-κB. In addition, furthermore
decreased NF-κB activity as a transcriptional activator and they
found that embelin reduced nuclear translocation of NF-κB.
Embelin suppressed proliferation of human glioma cells without
affecting the normal, immortalized human astrocytes. It also
has been reported to induce apoptosis in human glioma cells
by inhibiting NF-κB which plays an important role in cell
proliferation and survival of tumor. However, embelin has found
to show no inhibitory effect on XIAP in glioma cells, although
this active compound was discovered as an XIAP inhibitor.
Besides that, overexpression of p65 was decreased in embelin
induced apoptosis glioma cells. So, they concluded that embelin
could be a potent novel therapeutic compound by blocking
cancer cell proliferation and inducing apoptosis through NF-κB
inhibition.
Mitochondrial Pathway
On the other hand, in support of the above finding, Wang
et al. (2013) investigated the role of mitochondrial pathway
played in embelin-induced brain glioma cell apoptosis and the
effect of embelin on the cell cycle. Expression of apoptosis-
associated proteins, Bcl-2, Bcl-xL, Bax, and Bak, as well as
cytochrome-c levels, were determined by performing western
blot analysis. Embelin was found to be apoptotic to brain glioma
cells in a time and dose-dependent manner. The observed effect
could be due to arrest of the cell cycle in the G0/G1 phase.
Changes in mitochondrial membrane potential were caused by
embelin in brain glioma cell. Additionally, embelin regulated the
shifting of Bax and Bcl-2 to promote the mitochondrial release
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of cytochrome c, thus activating the caspase proteins to cause
apoptosis. Thus, embelin induces apoptosis in brain glioma cells
is closely associated with themitochondrial pathway (Wang et al.,
2013).
Blood-Brain Barrier (BBB)—Cerebral
Ischemia
Blood-brain barrier plays an important role in drug delivery to
the CNS. Blood-brain barrier restricts, facilitates and regulates
many substances from entering the CNS. It also secretes
substances into the blood and the CNS (Banks, 2009). The entry
of compounds across the BBB depends on their lipid solubility
based on the estimation of oil/water partition coefficient (Laterra
and Betz, 1999). Besides that, molecular weight, charge, tertiary
structure and degree of protein binding are also among the
factors in addition to lipid solubility affecting the ability of a drug
to cross the BBB (Banks, 2009).
According to Pathan et al. (2009) a drug is likely to be able
to transport across the BBB, if it possesses some important
properties like, the compound should be in un-ionized form,
partition coefficient (log P)-value should be near 2, molecular
weight must be <400 Da and cumulative number of hydrogen
bonds should not go beyond 8–10. According to this embelin
is un-ionized molecule with log P-value of 4.83, the molecular
weight is 294.38 and cumulative H bonds are 6. These properties
of embelin make it permeable to BBB. So far, not a single
study reported BBB permeability of embelin in in-vitro model.
However, Siegel et al. (2011) performed in-vivo BBB permeability
study and reported that embelin could cross the BBB. They
performed liquid chromatography/tandem mass spectrometry
(LC-MS/MS) on male and female sham and stroke brains.
Embelin (20 mg/kg s.c.) was dosed for 3 days and it was found
that the brain concentrations were elevated in both the sham and
stroke mice, but the level was significantly higher in stroke mice
which were close to reported IC50 for embelin (4.1± 1.1 µM).
Safety and Toxicity
Acute toxicity studies in mice treated with embelin 50 and 100
mg/kg oral dose showed no significant body weight change,
mortality or apparent toxic effects, signifying its safety profile.
This study suggests that embelin is safe on acute administration
(Gupta et al., 1976). The LD50-value of embelin was reported as
44 mg/kg by i.p. route. Embelin in doses of 10mg to 3 g/kg given
orally to rats and mice did not show any toxic effects. Subacute
toxicity on 10 weeks administration of 10 mg/kg of embelin to
rats also indicated the drug to be free from toxic effects on heart,
liver, kidney, and bone marrow, thereby having a high margin of
safety in acute toxicity studies (Rathinam et al., 1976).
The toxicity of emblin has been assessed in female cyclic rats.
Its administration at a dose of 120 mg/kg body weight did not
cause any changes in the weight of liver, kidney, and spleen,
however, the wet weight of the adrenals showed a remarkable
increase. Biochemical constituents such as protein and glycogen
did not show any change in these organs except in the adrenal
where a significant increase was observed. The activity of acid and
alkaline phosphatase was increased in the kidney and adrenal.
These toxic effects seem to be due to exposure of a very high dose
i.e., 120 mg/kg, whereas LD50 reported was around 44 mg/kg.
Administration of embelin for 6 weeks caused severe
pathological changes in the liver and kidney which mainly
included disintegration, necrotic changes, and perinuclear
vacuolation. Marked tubular damage was observed in the
kidneys. The adrenals showed hypertrophy and the histological
features of the spleen remained unchanged (Prakash, 1994). In
chronic toxicity study, the administration of embelin to Wistar
rats at a dose of 50 mg/kg/day for 14 weeks did not cause
any extreme drop in the blood counts but showed toxic effects
on the hematopoietic cells (Sreepriya and Bali, 2006). Previous
studies had also reported the non-toxic nature of embelin on
hematopoietic cells when administered for 6 months in mice,
rats, and monkeys (Radhakrishnan and Gnanamani, 2014).
For in-vitro cytotoxicity studies, embelin showed the toxic
effect at 217 µg /ml to lung fibroblasts (Feresin et al., 2003). IC50
of 16.85 and 27.52 µM of embelin was calculated against mouse
lymphocytes and mouse macrophages, respectively (Sreepriya
and Bali, 2006). Isolated ovarian cells were directly challenged
with embelin and showed a direct effect on isolated ovarian cells
(Simukoko, 2000). It did not show the toxic effect on human
fibroblasts at 20µg/ml for 72 h in an in-vitro setting. Embelin was
most active against sarcoma (XC) cells after 72 h of incubation
(ED50 8µg/ml) and slightly less active againstMurinemelanoma
(B16) cells (ED50 13 µg/ml). An encouraging observation is a
fact, that at these concentrations, embelin did not affect normal
cells (HSF; Podolak et al., 2005).
Overall toxicity studies revealed that embelin at therapeutic
doses found to be non-toxic and safe to use. Higher doses of
embelin exhibit some sort of toxicity, but these doses are well
above LD50-value and toxic effects are verymuch expected. There
is also a need to carry out detailed toxicity study of embelin as
per the International Council for Harmonization (ICH) safety
guidelines.
CONCLUSION AND FUTURE DIRECTIONS
Embelin is the main constituent found in the plant E. ribes.
Embelin posses favorable physical and chemical properties and its
ability to cross the blood brain barriermake it a suitable candidate
for the treatment of CNS disorders. In the present systematic
review, an attempt was made to compile and discuss the efficacy
of embelin against CNS complications. Embelin had been studied
using various in-vitro prototypes and in-vivo animal models.
It is well-reported that embelin exhibit strong anticonvulsant,
anxiolytic, antidepressant properties and also improve conditions
like sickness behavior, Huntington’s disease, multiple sclerosis,
cerebral ischemia and TBI.
Although a vast number of activities have been reported
with embelin in experimental settings, there is not a single
human study found on embelin related to CNS activity. None
of the animal experimental outcomes was translated into human
clinical research. One of the potential reasons for the non-
translational research could be a lack of detailed safety and
toxicity profile. Future pre-clinical and clinical trials are required
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to support the safety and efficacy of this active compound. Once
safety profile is established, embelin should be taken up for
clinical trials. As embelin is being studied for a rich number of
CNS activities, a controlled human clinical trial will open up a
new horizon for this promising molecule.
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